Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
Related Questions
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
What is the preferred osteoporosis therapy after completing teriparatide in a young woman planning pregnancy within the next year?
Is there a maximum duration for raloxifene use?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Would you consider the use of romosozumab in men who have failed therapy with teriparatide and sustained multiple vertebral fractures?
Is there an evidence-based consensus on CT-derived Hounsfield unit thresholds for opportunistic assessment of osteoporosis, and how should such measurements be applied when DXA results are inconclusive or do not meet diagnostic criteria?
